当前位置:首页 - 行情中心 - 药康生物(688046) - 财务分析 - 现金流量表

药康生物

(688046)

  

流通市值:84.46亿  总市值:84.46亿
流通股本:4.10亿   总股本:4.10亿

现金流量表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金166,842,991.98812,900,801.53513,933,061.3307,841,303.42
  收到的税费返还-11,382.7211,382.72-
  收到其他与经营活动有关的现金9,813,127.2332,315,320.6218,342,467.769,912,469.03
  经营活动现金流入小计176,656,119.21845,227,504.87532,286,911.78317,753,772.45
  购买商品、接受劳务支付的现金52,249,496.8168,542,140.18129,978,572.5290,518,048.15
  支付给职工以及为职工支付的现金105,168,775.91313,880,735.66243,405,353.33171,511,317.44
  支付的各项税费8,616,224.8129,293,515.5717,131,592.711,210,555.78
  支付其他与经营活动有关的现金14,711,535.43106,484,116.4154,597,068.5629,248,872.47
  经营活动现金流出小计180,746,032.95618,200,507.82445,112,587.11302,488,793.84
  经营活动产生的现金流量净额-4,089,913.74227,026,997.0587,174,324.6715,264,978.61
二、投资活动产生的现金流量:
  收回投资收到的现金11,657,534.25---
  取得投资收益收到的现金6,094,697.2617,238,865.0310,402,185.296,066,539.45
  处置固定资产、无形资产和其他长期资产收回的现金净额-155,392.4313,00013,000
  收到的其他与投资活动有关的现金922,200,041.712,549,316,558.351,735,548,888.9913,387,333.34
  投资活动现金流入小计939,952,273.222,566,710,815.811,745,964,074.19919,466,872.79
  购建固定资产、无形资产和其他长期资产支付的现金15,579,872.11104,989,859.4495,760,358.5171,418,745.65
  投资支付的现金-15,510,00015,510,00014,010,000
  支付其他与投资活动有关的现金954,112,928.442,912,791,174.072,228,152,969.181,180,702,135.85
  投资活动现金流出小计969,692,800.553,033,291,033.512,339,423,327.691,266,130,881.5
  投资活动产生的现金流量净额-29,740,527.33-466,580,217.7-593,459,253.5-346,664,008.71
三、筹资活动产生的现金流量:
  吸收投资收到的现金-14,524,800--
  取得借款收到的现金29,210,000298,490,282.88255,168,663.99220,450,000
  收到其他与筹资活动有关的现金--11,249,60011,249,600
  筹资活动现金流入小计29,210,000313,015,082.88266,418,263.99231,699,600
  偿还债务支付的现金58,418,663.99199,209,444.4487,902,777.7867,952,777.78
  分配股利、利润或偿付利息支付的现金353,162.7661,223,026.8748,030,922.512,020,919.81
  支付其他与筹资活动有关的现金3,684,722.6925,688,891.921,178,064.4411,302,726.93
  筹资活动现金流出小计62,456,549.44286,121,363.21157,111,764.7381,276,424.52
  筹资活动产生的现金流量净额-33,246,549.4426,893,719.67109,306,499.26150,423,175.48
四、汇率变动对现金及现金等价物的影响-4,357,164.26-2,614,681.6754,614.881,744,503.74
  现金及现金等价物净增加额平衡项目00-0.010
五、现金及现金等价物净增加额-71,434,154.77-215,274,182.65-396,923,814.7-179,231,350.88
  加:期初现金及现金等价物余额485,912,238.51701,215,442.73701,215,442.73701,215,442.73
  期末现金及现金等价物余额平衡项目-0.01000
  期末现金及现金等价物余额414,478,083.73485,941,260.08304,291,628.03521,984,091.85
补充资料:
  净利润-142,636,806.31-70,905,477.14
  资产减值准备-19,772,588.85-8,308,552.96
  固定资产和投资性房地产折旧-70,235,754.1-35,748,942.78
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-70,235,754.1-35,748,942.78
  无形资产摊销-4,887,300.79-2,256,109.66
  长期待摊费用摊销-11,805,027.82-5,994,118.06
  处置固定资产、无形资产和其他长期资产的损失-36,167.9-25,422.09
  公允价值变动损失--693,494.32--372,000.14
  财务费用-6,984,234.86-915,290.03
  投资损失--8,746,616.58--1,351,054.93
  递延所得税-2,573,559.42--2,807,207.92
  其中:递延所得税资产减少-2,843,244.72--3,617,398.16
    递延所得税负债增加--269,685.3-810,190.24
  存货的减少--18,764,386.12--8,045,852.22
  经营性应收项目的减少--56,606,788.09--73,266,368.56
  经营性应付项目的增加-22,202,617.21--39,999,279.4
  其他-7,822,656.34-1,908,565.55
  不涉及现金收支的投资和筹资活动金额其他项目-68,531,740.14--
  现金的期末余额-485,941,260.08-521,984,091.85
  减:现金的期初余额-701,215,442.73-701,215,442.73
  现金及现金等价物的净增加额--215,274,182.65--179,231,350.88
公告日期2026-04-232026-04-232025-10-232025-08-23
审计意见(境内)标准无保留意见
TOP↑